StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultApr 9, 2026, 04:07 PM

NEOGEN CORP Files Q3 2026 Quarterly Report, Reports 217.7M Shares Outstanding

AI Summary

NEOGEN CORP (NEOG) has filed its quarterly report for the period ended February 28, 2026. The filing confirms the company's status as a large accelerated filer and its compliance with SEC reporting requirements. As of the reporting date, the company had 217,673,041 shares of common stock outstanding. The full report, which includes interim condensed consolidated financial statements and management's discussion and analysis, will provide detailed insights into the company's performance for the quarter.

Key Highlights

  • NEOGEN CORP (NEOG) filed its Quarterly Report (10-Q) for the period ended February 28, 2026.
  • As of February 28, 2026, there were 217,673,041 shares of Common Stock outstanding.
  • The company is classified as a large accelerated filer.
  • The filing confirms NEOGEN has filed all required reports and submitted all Interactive Data Files during the preceding 12 months.